Boule appoints Annette Colin as CFO

Boule Diagnostics AB appoints Annette Colin as its new CFO effective April 4th, 2022.

Annette Colin brings more than 25 years of experience from executive positions such as CEO, CFO, COO, and Group Financial Controller, including 15+ years in the Life Science industry. Annette has worked in fast-growing companies and has a long and broad experience in finance as well as in building strategic planning, streamlining infrastructure, raising capital, and managing investor relations. She has been involved in several M&A and IPO transactions and has been working with companies of all sizes, from start-ups to Large Cap companies. Her most recent assignment was as CFO at Biotage AB. Before that she held leading positions at the listed companies Annexin Pharmaceuticals, Observe Medical, Stille, Lindab, Perbio Science and as a consultant at Ernst & Young.

“I am really looking forward to taking Boule to the next level together with the team. With the new product platform, I see potential both in terms of increased growth, profitability and an increase in shareholder value.” says Annette Colin.

I’m very pleased that Annette will join Boule. She brings strong expertise within finance as well as broad experience from business development. Boule is in an expansive phase with several strategic initiatives for growth and innovation, not least the launch of a new product platform. In this context, I’m convinced Annette will utilize her extensive knowledge and drive to create value for Boule.” says CEO and Group President, Jesper Söderqvist.

Current CFO, Christina Rubenhag, will be available to the company during April and her employment at Boule ends on April 30th.

For more information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)70-546 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011.

The information was submitted for publication, through the agency of the contact person set out above, at 08:40 CET on January 17, 2022.

Boule Diagnostics appoints new CFO

  • Subscribe to our news